GSK598809 is being developed as an innovative treatment for substance dependence and potentially other compulsive behavioral disorders. This study will asses the effects of a single dose of GSK598809 in modulating nicotine reward in 2 cohorts of otherwise healthy male volunteers who smoke. Each cohort of subjects will receive a single dose of placebo or GSK598809 in two dosing sessions binded crossover fashine. There will be a washout period of at least seven days between each session.
Study Type
INTERVENTIONAL
Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Enrollment
29
Drug
GSK Investigational Site
Philadelphia, Pennsylvania, United States
Pharmacokinetics
Time frame: through 24 hours
Stroop test
Time frame: through 10 hours
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.